Teclistamab Regimen Approved for Relapsed/Refractory Multiple Myeloma

The Food and Drug Administration (FDA) approved a new combination therapy on March 5, 2026, for adults battling relapsed or refractory multiple myeloma – a cancer that forms in plasma cells. The approval brings together teclistamab (Tecvayli), manufactured by Janssen Biotech, Inc. and daratumumab hyaluronidase-fihj, offering a new option for patients whose disease has returned or worsened after prior treatment. This approval also expands the use of teclistamab as a standalone therapy for those who have already undergone at least four lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistamab initially received accelerated approval for this single-agent use in 2022.

Understanding Multiple Myeloma and Treatment Challenges

Multiple myeloma is a cancer of plasma cells, a type of white blood cell responsible for producing antibodies. When these cells become cancerous, they multiply uncontrollably, crowding out healthy cells in the bone marrow and leading to a range of complications. Treatment often involves chemotherapy, immunotherapy, and stem cell transplantation. However, many patients eventually experience relapse or become refractory to available therapies, highlighting the need for new treatment options. The combination approved this week addresses this critical gap, specifically for patients who have already received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

MajesTEC-3 Trial: Evidence Supporting the Approval

The FDA’s decision is based on data from the MajesTEC-3 clinical trial (NCT05083169), a randomized, open-label study involving 587 patients. Participants were divided into two groups: 291 received the teclistamab-daratumumab combination, while the remaining 296 received either daratumumab hyaluronidase-fihj, pomalidomide, and dexamethasone (DPd) or daratumumab hyaluronidase-fihj, bortezomib, and dexamethasone (DVd) – standard treatment regimens. The primary goal of the trial was to assess progression-free survival (PFS), meaning the length of time patients lived without their disease worsening. Results published in the New England Journal of Medicine demonstrated a significant benefit for those receiving the combination therapy.

Median PFS was not reached in the teclistamab and daratumumab arm, meaning the study hasn’t yet observed enough events to calculate a median time. In contrast, the control arm had a median PFS of 18.1 months. This translates to a hazard ratio of 0.17 (95% confidence interval: 0.12-0.23), indicating a substantial reduction in the risk of disease progression for those on the combination therapy. Patients in the teclistamab-daratumumab group experienced higher rates of complete response or better (81.8% vs. 32.1%) and minimal residual disease negativity (58.4% vs. 17.1%) compared to the control group. As detailed in PubMed, these findings suggest a deeper and more durable response to treatment.

How Teclistamab and Daratumumab Work

Teclistamab is a bispecific antibody, meaning it’s engineered to bind to two different targets simultaneously. In this case, it targets CD3, a protein found on T-cells (immune cells), and B-cell maturation antigen (BCMA), a protein found on myeloma cells. By bringing these two cells together, teclistamab directs the T-cells to attack and kill the myeloma cells. Daratumumab, is a monoclonal antibody that targets CD38, another protein found on the surface of myeloma cells. It works by marking the myeloma cells for destruction by the immune system. Combining these two therapies leverages different mechanisms to enhance the body’s ability to fight the cancer.

Safety Considerations and Adverse Events

While the combination therapy showed promising efficacy, it’s important to acknowledge potential side effects. Serious adverse events occurred in 70.7% of patients in the teclistamab-daratumumab group, compared to 62.4% in the control group. Deaths attributed to adverse events were reported in 7.1% and 5.9% of patients, respectively. These findings underscore the need for careful monitoring and management of potential side effects by healthcare professionals. The full prescribing information for Tecvayli, including a complete list of adverse events, will be available on the FDA’s Drugs@FDA website.

What This Approval Means for Patients

This approval represents a significant step forward in the treatment of relapsed or refractory multiple myeloma. Patients who have exhausted other treatment options now have a new, potentially highly effective therapy available to them. The MajesTEC-3 trial data suggest that the combination of teclistamab and daratumumab can lead to longer periods without disease progression and improved response rates. However, it’s crucial to remember that this therapy is not a cure, and individual responses may vary. Patients should discuss the potential benefits and risks of this treatment with their oncologist to determine if it’s the right option for them.

Looking Ahead: Ongoing Research and Surveillance

The FDA’s approval was part of the Commissioner’s National Priority Review Voucher program, designed to expedite the review of products addressing critical national priorities. This highlights the urgency of finding new treatments for serious diseases like multiple myeloma. Ongoing surveillance will be essential to monitor the long-term safety and effectiveness of the teclistamab-daratumumab combination in real-world settings. Further research may also explore the potential of this combination in earlier lines of therapy or in combination with other agents. The FDA will continue to review data as it becomes available and may update its guidance accordingly. Patients and healthcare providers should stay informed about the latest developments in multiple myeloma treatment by consulting reputable sources such as the National Cancer Institute and the Multiple Myeloma Research Foundation.